Clinical relevance of the urokinase plasminogen activator system in breast cancer

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy

1992 • 2,084 citations

The urokinase-type plasminogen activator system in cancer metastasis: A review

1997 • 1,561 citations

Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration

1997 • 472 citations

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

1993 • 396 citations

Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy

1997 • 391 citations

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

1993 • 367 citations

Proteases as prognostic markers in cancer.

1996 • 319 citations

Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

1988 • 294 citations

Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

1990 • 294 citations

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

1992 • 239 citations

Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer

1991 • 236 citations

Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.

1994 • 230 citations

Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer

1990 • 189 citations

Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.

1995 • 175 citations

Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer

1995 • 161 citations

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas

1994 • 159 citations

Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer

1995 • 150 citations

Multiparametric Prognostic Evaluation of Biological Factors in Primary Breast Cancer

1992 • 125 citations

Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

1994 • 123 citations

Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.

1995 • 106 citations

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer

1998 • 104 citations

Type‐1 plasminogen activator inhibitor in human breast carcinomas

1992 • 100 citations

6 The urokinase/urokinase-receptor system and cancer invasion

1995 • 74 citations

Plasminogen activator inhibitor type 2 in breast cancer

1997 • 72 citations

Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop

1996 • 71 citations

Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer

1994 • 70 citations

Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay

1996 • 64 citations

Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer

1997 • 61 citations

Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease

1998 • 56 citations

Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.

1998 • 53 citations

Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients

1997 • 51 citations

Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer

1995 • 49 citations

Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence

1998 • 47 citations

Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours

1991 • 46 citations

Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.

1997 • 45 citations

Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer

1997 • 44 citations

Urokinase-plasminogen activator in breast cancer

1991 • 34 citations

Urokinase Plasminogen Activator as a Predictor of Aggressive Disease in Breast Cancer

1996 • 34 citations

Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer

1993 • 33 citations

Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.

1998 • 32 citations

Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): Regulators of proteolysis during cancer invasion and prognostic parameters in Breast cancer

1994 • 30 citations

Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.

1998 • 24 citations

Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods

1998 • 17 citations

Hormone-dependent cancer

1996 • 16 citations

A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue

1997 • 11 citations